Enanta Pharma (ENTA) Tops Q1 EPS by 10c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2019
February 6, 2020 4:00 PM ESTWebcast and Conference Call Today at 4:30 p.m. ET
Positive results from part 1 of the Phase 1a/b clinical study of EDP-514 in healthy subjects- Part 2 initiated in nuc-suppressed chronic hepatitis B virus patients Research and development programs progressing well -- several milestones expected in 2020 from our RSV, NASH, and HBV programs Royalty revenue for the quarter was $52.6 million Cash and marketable securities totaled $414.7 million at December 31, 2019
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:... More
